THE IMPACT OF INCENTIVES FOR VACCINATION: THIRD DOSE UPTAKE SURVEY

Last registered on June 15, 2022
View Trial History

Pre-Trial

Trial Information

General Information

Title
THE IMPACT OF INCENTIVES FOR VACCINATION: THIRD DOSE UPTAKE SURVEY
RCT ID
AEARCTR-0009580
Initial registration date
June 14, 2022

Initial registration date is when the trial was registered.

It corresponds to when the registration was submitted to the Registry to be reviewed for publication.

First published
June 15, 2022, 10:15 AM EDT

First published corresponds to when the trial was first made public on the Registry after being reviewed.

Locations

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information

Primary Investigator

Name
Florian Schneider
Affiliation
University of Zurich
Contact Primary Investigator

Other Primary Investigator(s)

PI Name
Armando Meier
PI Affiliation
University of Lausanne
PI Name
Pol Campos-Mercade
PI Affiliation
University of Copenhagen
PI Name
Stephan Meier
PI Affiliation
Columbia University
PI Name
Devin Pope
PI Affiliation
University of Chicago
PI Name
Erik Wengström
PI Affiliation
Lund University

Additional Trial Information

Status
In development
Start date
2022-06-15
End date
2024-06-17
Keywords
Behavior, Health
Additional Keywords
JEL code(s)
Secondary IDs
Prior work
This trial is based on or builds upon one or more prior RCTs.
Abstract
We study the long-term impacts of offering monetary incentives for vaccination on future vaccination uptake. To do so, we exploit the setting of an earlier study that offered payment to people for getting a first dose of a COVID-19 vaccine (Campos-Mercade et al., 2021), which provides us with random variation in exposure to monetary incentives. In a survey, we ask participants whether they got a third dose of the COVID-19 vaccine (booster shot).
External Link(s)

Registration Citation

Citation
Campos-Mercade, Pol et al. 2022. "THE IMPACT OF INCENTIVES FOR VACCINATION: THIRD DOSE UPTAKE SURVEY." AEA RCT Registry. June 15. https://doi.org/10.1257/rct.9580-1.0
Sponsors & Partners
Experimental Details

Interventions

Intervention(s)
Intervention Start Date
2022-06-15
Intervention End Date
2022-06-27

Primary Outcomes

Primary Outcomes (end points)
Have you taken a third dose of a COVID-19 vaccine? (Yes/No)
Primary Outcomes (explanation)

Secondary Outcomes

Secondary Outcomes (end points)
Secondary Outcomes (explanation)

Experimental Design

Experimental Design
We focus on the participants in the Incentives, Control and the No reminders conditions of Campos-Mercade et al. (2021). The Control condition and the No reminders condition did not include any interventions to increase vaccination uptake. In the Incentives condition, participants were offered a monetary incentive of SEK 200 (about US$24) if they got vaccinated within 30 days of the vaccine becoming available to them. We conduct a survey with these participants.
Experimental Design Details
Not available
Randomization Method
Randomization in Campos-Mercade et al. (2021) was done by a computer
Randomization Unit
Randomization in Campos-Mercade et al. (2021) was done at the individual level.
Was the treatment clustered?
No

Experiment Characteristics

Sample size: planned number of clusters
The surveys are collected through an online survey with the help of the Swedish survey company Norstat. We aim at recruiting as many participants in the Incentives, Control and No reminders conditions of Campos-Mercade et al. (2021) as possible. We expect around 2500 participants to participate in the survey.
Sample size: planned number of observations
We expect around 2500 participants to participate in the survey.
Sample size (or number of clusters) by treatment arms
We expect around 2500 participants to participate in the survey.
Minimum detectable effect size for main outcomes (accounting for sample design and clustering)
Supporting Documents and Materials
IRB

Institutional Review Boards (IRBs)

IRB Name
Etikprövningsmyndigheten
IRB Approval Date
2021-12-14
IRB Approval Number
2021-06367-02
Analysis Plan